EFSA approves nutrition claims for omega-3s

Related tags Nutrition

Europe's food risk assessment body has issued its opinion on
nutrition claims for products containing omega-3 fatty acids, which
will be used in forthcoming laws on nutrition and health claims.

The European Food Safety Authority (EFSA) was asked by the European Commission to review the scientific merits of claims proposed for addition to the annex of the law, still under debate by European officials.

EFSA's panel on dietetic products, nutrition and allergies approved all of the proposed claims, stipulating in each case which kinds of foods could carry the claims.

They include 'omega-3 fatty acid source', which must contain more than 15 per cent of the daily recommended nutritional intake (2g/day for an adult male) per 100g/100ml, and 'high in omega-3 fatty acids'. For this second claim the food must contain more than 30 per cent of the RNI.

Other nutrition claims that could be used include 'high monounsaturated fat', 'high polyunsaturated fat' and 'high unsaturated fat', each with specific conditions.

The claims, specifically those referring to 'omega-3 fatty acids', will be important as consumers become increasingly aware of the health benefits of these fats.

Claims making a direct reference to these health benefits, or 'health claims', have not yet been finalised by the Commission and are likly to be more eagerly awaited by many food makers than nutrition claims.

Europe's nutrition and health claims law is scheduled to go through a second reading in parliament at the end of the year. If passed, these nutrition claims would apply for all member states.

More information on the opinion can be found here​.

Related topics Ingredients

Related news

Related products

show more

What consumers are looking for in alcohol drinks

What consumers are looking for in alcohol drinks

Content provided by ADM | 12-Apr-2024 | Application Note

Are you ready to understand the consumer insights driving the future of the alcoholic beverage market? We've assembled a consumer insights report...

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-Apr-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

Related suppliers

Follow us

Products

View more

Webinars